A multicenter, randomized, double-blind, placebo controlled phase III study of panobinostat in combination with bortezomib and dexamethasone in patients with relapsed multiple myeloma

Phase 3

Recruiting

• Conditions: 10025320; Kahler's disease; Multiple Myeloma

• Registration Number: NL-OMON38264
• Lead Sponsor: ovartis

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Last Update Posted: 6 May 2024

Recruitment & Eligibility

• Status: Recruiting
• Sex: Not specified
• Target Recruitment: 15

Inclusion Criteria

1. Patient has a previous diagnosis of multiple myeloma, based on IMWG 2003 definitions. All three of the following criteria must have been met:
a. Monoclonal immunoglobulin (M component) on electrophoresis, and on immunofixation on serum or on total 24 hour urine
b. Bone marrow (clonal) plasma cells >= 10% or biopsy proven plasmacytoma
c. Related organ or tissue impairment (CRAB symptoms: anemia, hypercalcemia, lytic bone lesions, renal insufficiency, hyperviscosity, amyloidosis or recurrent infections)
2. Patient with 1 to 3 prior lines of therapy who require retreatment of myeloma (cf IMWG 2003 ) for one of the 2 conditions below:
a. Relapsed, defined by disease that recurred in a patient that responded under a prior therapy, by reaching a MR or better, and had not progressed under this therapy nor up to 60 days of last dose of this therapy. Patients priorly treated by BTZ may be eligible.
b. Relapsed-and-refractory to a therapy, provided that meets both conditions:
- patient has relapsed to at least one prior line
- and patient was refractory to another line (except Bortezomib), by either not reaching a MR, or progressed while under this therapy, or within 60 days of its last dose
3. Patient has measurable disease on M protein at study screening defined by at least one of the following measurements as per thresholds clarified in IMWG 2003 disease definitions (Kyle, et al 2003):
• Serum M-protein >= 1 g/dL (>= 10 g/L)
• Urine M-protein >= 200 mg/24 h
4. Patients treated with local radiotherapy with or without concomitant exposure to steroids for pain control or management of cord/nerve root compression, are eligible. Two weeks must have lapsed since last date of radiotherapy, which is recommended to be a limited field. Patients who require concurrent radiotherapy should have entry to the protocol deferred until the radiotherapy is completed and 2 weeks have passed since the last date of therapy
6. ECOG performance status of <= 2
7. Patient has the following laboratory values within 3 weeks before starting study drug
a. Absolute neutrophil count >= 1.5 x 109 /L
b. Platelet count >= 100 x 109 /L
c. Serum potassium, magnesium, phosphorus, within normal limits (WNL) for institution
d. Total calcium (corrected for serum albumin) or ionized calcium >= LLN, and not higher than CTCAE grade 1 in case of elevated value
e. AST/SGOT and ALT/SGPT <= 2.5 x ULN
f. Serum total bilirubin <= 1.5 ULN (or <= 3.0 x ULN if patient has Gilbert syndrome)
g. Serum creatinine levels <= 1.5 x ULN, or calculated creatinine clearance >= 60 ml/min

Exclusion Criteria

1. Patients who have progressed under all prior lines of anti MM therapy
2. Patients who have been refractory to prior Bortezomib
3. Allogeneic stem cell transplant recipient presenting with graft versus host disease either active or requiring immunosuppression
4. Patient has shown intolerance to bortezomib or to dexamethasone or components of these drugs or has any contraindication to one or the other drug, following locally applicable prescribing information
5. Patient has grade >= 2 peripheral neuropathy or grade 1 peripheral neuropathy with pain on clinical examination within 14 days before randomization
6. Patient received prior treatment with deacetylase inhibitors including panobinostat
7. Patient needing valproic acid for any medical condition during the study or within 5 days prior to first administration of panobinostat/study treatment
8. Patient taking any anti-cancer therapy concomitantly (bisphosphonates are permitted only if commenced prior to the start of screening period)
9. Patient has another primary malignancy < 3 years from first dose of study treatment
10. Patient who received:
a. prior anti-myeloma chemotherapy or medication including IMiDs and Dexamethasone <= 3 weeks prior to start of study.
b. experimental therapy or biologic immunotherapy including monoclonal antibodies <= 4 weeks prior to start of study.
c. prior radiation therapy <= 4 weeks or limited field radiotherapy <= 2 weeks prior start of study.
11. Patient has not recovered from all therapy-related toxicities associated with above listed treatments to < grade 2 CTCAE.
12. Patient has undergone major surgery <= 2 weeks prior to starting study drug or who have not recovered from side effects of such therapy to < grade 2 CTCAE
13. Patients with evidence of mucosal or internal bleeding
14. Patient has unresolved diarrhea >= CTCAE grade 2
15. Patient has impaired cardiac function, including any one of the following:
a. Left Ventricular Ejection Fraction < LLN of institutional norm, as determined by ECHO or MUGA
b. obligate use of a permanent cardiac pacemaker
c. congenital long QT syndrome
d. history or presence of ventricular tachy-arrhythmias
e. resting bradycardia defined as < 50 beats per minute
f. QTcF > 450 msec on screening ECG
g. complete left bundle branch block, bifascicular block
h. any clinically significant ST segment and/or T-wave abnormalities
i. presence of unstable atrial fibrillation. Patients with stable atrial fibrillation can be enrolled provided they do not meet other cardiac exclusion criteria.
j. myocardial infarction or unstable angina pectoris <= 6 months prior to starting study drug
k. symptomatic congestive heart failure
l. other clinically significant heart disease and vascular disease
16. Patient taking medications with relative risk of prolonging the QT interval or inducing Torsade de pointes, if such treatment cannot be discontinued or switched to a different medication prior to starting study drug

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
<p>Progession Free Survival (PFS).</p><br>

Secondary Outcome Measures

Name	Time	Method
<p>Overall survival, duration of response, percentage (near) complete responses,<br /><br>safety of the combination therapy, health-related quality of life and symptoms<br /><br>of MM.</p><br>